Premium
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism
Author(s) -
Ariizumi Ken,
Ohara Shuichi,
Koike Tomoyuki,
Inomata Yoshifumi,
Iijima Katsunori,
Sekine Hitoshi,
Noguchi Mitsunori,
Sugiyama Koichi,
Eda Yoshiki,
Kayaba Shoichi,
Kawamura Msashi,
Shimosegawa Tooru
Publication year - 2006
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2006.04190.x
Subject(s) - cyp2c19 , rabeprazole , medicine , omeprazole , gastroenterology , reflux esophagitis , lansoprazole , esophagitis , genotype , pharmacology , reflux , gene , biology , biochemistry , disease , cytochrome p450 , metabolism
Background: The acid suppressive effects of omeprazole (OPZ) and lansoprazole (LPZ) are influenced by the CYP2C19 polymorphism. On the other hand, some investigators have reported that acid suppressive effect of rabeprazole (RPZ) was not significantly affected by CYP2C19. The present study was designed to investigate whether the CYP2C19 genotype is related to the healing of reflux esophagitis (RE) in treatment with RPZ 10 mg. Methods: One hundred and three Japanese patients with RE were treated with daily oral administration of 10 mg RPZ. At 4 and 8 weeks after the start of treatment, healing of RE was evaluated endoscopically. The CYP2C19 genotype was investigated before the treatment. Results: At 4 weeks after the start of treatment, the healing rates for homo‐extensive metabolizer, hetero‐extensive metabolizer, and poor metabolizer patients were 86.1% (31/36), 92.0% (46/50), and 82.4% (14/17), respectively, and at 8 weeks after the start of treatment, the healing rates were 86.1% (31/36), 92.0% (46/50), and 82.4% (14/17), respectively. There were no significant differences in the healing rate of RE among the three genotypes at either 4 or 8 weeks after the start of treatment. Conclusions: The therapeutic effects of 10 mg/day RPZ administration on RE may be uninfluenced by the CYP2C19 polymorphism.